Pipeline
GlycoNex Initiates Second Biosimilar Program for Immune-Mediated Indications
An in-house monoclonal antibody biosimilar program addressing an immune-mediated disease.
Filing disclosure
NEWS
News & Announcements
Milestones, partnerships, and program updates from GlycoNex's glycan-directed oncology and biosimilar programs.
2026
4 entries
Regulatory
GNX1021 Cleared by Japan's PMDA to Begin First-in-Human Phase 1 Trial
Japan's Pharmaceuticals and Medical Devices Agency authorized first-in-human dosing for GlycoNex's lead glycan-targeted ADC in advanced gastrointestinal cancers.
Read release →
Partnership
GlycoNex and Nippon Kayaku Enter Co-Development Agreement for GNX201-ADC
A co-development agreement pairing GlycoNex's anti-glycan antibody discovery with Nippon Kayaku's clinical development expertise to advance a next-generation pro-antibody ADC.
Read release →
Corporate
GlycoNex Adopts Advanced AI Computing to Accelerate Anti-Glycan Antibody Development
Investment in advanced AI computing and models to accelerate next-generation anti-glycan antibody discovery.
Filing disclosure2025
6 entries
Partnership
GlycoNex Signs CDMO Agreement with Change Cure for HMGB1-Targeted Antibody Program
A contract development and manufacturing agreement for CC001, an HMGB1-targeted antibody for frontotemporal lobar degeneration (FTLD).
Press release
Clinical
GlycoNex and Hokkaido University Hospital Collaborate on Gastric Cancer ADC Research
A clinicopathological collaboration studying bLeB/Y expression in Japanese gastric cancer patients to support GNX1021's precision-medicine strategy.
Press release
Clinical
SPD8 Phase 3 Trial Completes Patient Enrollment
Enrollment completed for the Phase 3 trial of GlycoNex's denosumab biosimilar, with topline data anticipated in 2026.
Press release
Pipeline
GlycoNex Presents GNX1021 Preclinical Data
Preclinical data for the lead glycan-targeted ADC GNX1021.
Press release
Pipeline
GNX1021 Preclinical Data Presented at AACR 2025
Preclinical findings for GNX1021 presented at AACR 2025 and AACR-NCI-EORTC 2025.
Conference
Corporate
GlycoNex Participates in Biotech Showcase 2025 During J.P. Morgan Week
GlycoNex presented at Biotech Showcase 2025 during J.P. Morgan Healthcare week.
Conference